Research Article
Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study
Table 1
Baseline characteristics of 167 patients.
| Variables | n (%) |
| Ages (years) | Median age | 61.5 (35–83) | ≥65 | 66 (39.52) | Sex | Male | 129 (77.25) | Female | 38 (22.75) | Smoking history | Never-smoker | 98 (58.68) | Current or ex-smoker | 69 (41.32) | Histology | Nonsquamous | 111 (66.47) | Squamous | 56 (33.53) | Genetic mutation | EGFR | 22 (13.17) | ALK | 3 (1.80) | KARS | 11 (6.59) | Other | 16 (9.58) | None | 54 (32.34) | Unknown | 61 (36.53) | Pathological staging | III | 38 (20.75) | IV | 129 (77.25) | Therapy lines | First-line | 107 (64.07) | Posterior-line | 60 (35.93) | Presence of treating with antibiotic during immunotherapy | Yes | 54 (32.34) | No | 113 (67.66) | Types of PD-1 inhibitors used | Camrelizumab | 48 (28.74) | Sintilimab | 72 (43.11) | Toripalimab | 29 (17.37) | Camrelizumab, sintilimab | 5 (2.99) | Camrelizumab, toripalimab | 8 (4.79) | Sintilimab, toripalimab | 4 (2.40) | Camrelizumab, sintilimab, and toripalimab | 1 (0.60) |
|
|